These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. FUBP1 promotes neuroblastoma proliferation via enhancing glycolysis-a new possible marker of malignancy for neuroblastoma. Jiang P; Huang M; Qi W; Wang F; Yang T; Gao T; Luo C; Deng J; Yang Z; Zhou T; Zou Y; Gao G; Yang X J Exp Clin Cancer Res; 2019 Sep; 38(1):400. PubMed ID: 31511046 [TBL] [Abstract][Full Text] [Related]
11. Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression. Taylor JS; Zeki J; Ornell K; Coburn J; Shimada H; Ikegaki N; Chiu B J Pediatr Surg; 2019 Jun; 54(6):1192-1197. PubMed ID: 30879743 [TBL] [Abstract][Full Text] [Related]
12. Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2. Xiao D; Ren P; Su H; Yue M; Xiu R; Hu Y; Liu H; Qing G Oncotarget; 2015 Dec; 6(38):40655-66. PubMed ID: 26528759 [TBL] [Abstract][Full Text] [Related]
13. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors. Petroni M; Sardina F; Infante P; Bartolazzi A; Locatelli E; Fabretti F; Di Giulio S; Capalbo C; Cardinali B; Coppa A; Tessitore A; Colicchia V; Sahùn Roncero M; Belardinilli F; Di Marcotullio L; Soddu S; Comes Franchini M; Petricci E; Gulino A; Giannini G Cell Death Dis; 2018 Aug; 9(9):895. PubMed ID: 30166519 [TBL] [Abstract][Full Text] [Related]
14. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Tateishi K; Iafrate AJ; Ho Q; Curry WT; Batchelor TT; Flaherty KT; Onozato ML; Lelic N; Sundaram S; Cahill DP; Chi AS; Wakimoto H Clin Cancer Res; 2016 Sep; 22(17):4452-65. PubMed ID: 27076630 [TBL] [Abstract][Full Text] [Related]
15. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085 [TBL] [Abstract][Full Text] [Related]
16. Tumor origin of endothelial cells in human neuroblastoma. Pezzolo A; Parodi F; Corrias MV; Cinti R; Gambini C; Pistoia V J Clin Oncol; 2007 Feb; 25(4):376-83. PubMed ID: 17264333 [TBL] [Abstract][Full Text] [Related]
17. Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[ Li C; Huang S; Guo J; Wang C; Huang Z; Huang R; Liu L; Liang S; Wang H Mol Imaging Biol; 2019 Dec; 21(6):1117-1126. PubMed ID: 30850970 [TBL] [Abstract][Full Text] [Related]
18. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma. Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of thioredoxin-1 enhances the toxicity of glycolysis inhibitor 2-deoxyglucose by downregulating SLC1A5 expression in colorectal cancer cells. Tang T; Fang D; Ji Z; Zhong Z; Zhou B; Ye L; Jiang L; Sun X Cell Oncol (Dordr); 2024 Apr; 47(2):607-621. PubMed ID: 37867183 [TBL] [Abstract][Full Text] [Related]
20. Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model. Waldeck K; Cullinane C; Ardley K; Shortt J; Martin B; Tothill RW; Li J; Johnstone RW; McArthur GA; Hicks RJ; Wood PJ Int J Cancer; 2016 Jul; 139(1):194-204. PubMed ID: 26914605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]